What's new — Lung adenocarcinoma¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 14 |
| last 2 months | 34 |
| last 3 months | 36 |
| last 6 months | 46 |
| last year | 58 |
| older than a year | 263 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-05 | Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial — Lancet Respir Med ([PMID 42833236](https://pubmed.ncbi.nlm.nih.gov/42833236/){target="_blank" rel="noopener"}) | clinical-trials-landscape, egfr-disease |
| 2026-10-05 | Type II ROS1 Inhibition Overcomes Type I Inhibitor Resistance in ROS1 Fusion-Positive Lung Cancers: A Phase II Trial of Cabozantinib — Clin Cancer Res ([PMID 42832369](https://pubmed.ncbi.nlm.nih.gov/42832369/){target="_blank" rel="noopener"}) | alk-ros1-and-fusion-drivers |
| 2026-10-05 | Smoking Cessation Among Underserved Patients Referred for Lung Cancer Screening: A Randomized Clinical Trial — JAMA ([PMID 42832220](https://pubmed.ncbi.nlm.nih.gov/42832220/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2026-10-04 | Envonalkib Versus Crizotinib in Treatment-Naive ALK-Positive Non-Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study — MedComm (2020) ([PMID 42830869](https://pubmed.ncbi.nlm.nih.gov/42830869/){target="_blank" rel="noopener"}) | alk-ros1-and-fusion-drivers |
| 2026-10-03 | Trial-specific absolute disease-free survival effects of postoperative PD-1/PD-L1 blockade after complete resection of NSCLC: A systematic review — Lung Cancer ([PMID 42843316](https://pubmed.ncbi.nlm.nih.gov/42843316/){target="_blank" rel="noopener"}) | early-stage-and-perioperative-therapy |
| 2026-10-02 | Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.4 — J Clin Oncol ([PMID 42956324](https://pubmed.ncbi.nlm.nih.gov/42956324/){target="_blank" rel="noopener"}) | guidelines |
| 2026-10-02 | Local ablative therapy plus systemic treatment versus systemic therapy alone in oligometastatic non-small cell lung cancer: a systematic review and meta-analysis of randomized trials — Int J Clin Oncol ([PMID 42955614](https://pubmed.ncbi.nlm.nih.gov/42955614/){target="_blank" rel="noopener"}) | egfr-disease, systemic-therapy |
| 2026-10-02 | Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non-Small Cell Lung Cancer: The R-ALPS Randomized Clinical Trial — JAMA Oncol ([PMID 42955021](https://pubmed.ncbi.nlm.nih.gov/42955021/){target="_blank" rel="noopener"}) | clinical-trials-landscape, early-stage-and-perioperative-therapy |
| 2026-10-02 | KEYNOTE-867: A Phase III, Randomized, Double-Blind Study of Stereotactic Body Radiotherapy With Pembrolizumab for Unresected Stage I or II Non-Small Cell Lung Cancer — J Clin Oncol ([PMID 42950173](https://pubmed.ncbi.nlm.nih.gov/42950173/){target="_blank" rel="noopener"}) | clinical-trials-landscape, early-stage-and-perioperative-therapy |
| 2026-10-02 | Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China — Lancet ([PMID 42933461](https://pubmed.ncbi.nlm.nih.gov/42933461/){target="_blank" rel="noopener"}) | clinical-trials-landscape, egfr-disease, systemic-therapy |
| 2026-10-02 | Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China — Lancet ([PMID 42933457](https://pubmed.ncbi.nlm.nih.gov/42933457/){target="_blank" rel="noopener"}) | clinical-trials-landscape, egfr-disease, systemic-therapy |
| 2026-10-02 | Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC — N Engl J Med ([PMID 42929675](https://pubmed.ncbi.nlm.nih.gov/42929675/){target="_blank" rel="noopener"}) | clinical-trials-landscape, kras-braf-met-her2, systemic-therapy |
| 2026-10-02 | Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial — J Clin Oncol ([PMID 42928710](https://pubmed.ncbi.nlm.nih.gov/42928710/){target="_blank" rel="noopener"}) | clinical-trials-landscape, egfr-disease, kras-braf-met-her2 |
| 2026-10-02 | Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020) — Ann Oncol ([PMID 42927854](https://pubmed.ncbi.nlm.nih.gov/42927854/){target="_blank" rel="noopener"}) | clinical-trials-landscape, immunotherapy, systemic-therapy |
| 2026-10-01 | Development and Validation of a Blood Test Informed Risk Prediction Model for Lung Cancer-The Copenhagen Lung Cancer Risk Model (CPH-Lung) — J Clin Oncol ([PMID 42863103](https://pubmed.ncbi.nlm.nih.gov/42863103/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2026-10-01 | Correction to Lancet Oncol 2026; 27: 1094-109 — Lancet Oncol ([PMID 42805208](https://pubmed.ncbi.nlm.nih.gov/42805208/){target="_blank" rel="noopener"}) | egfr-disease |
| 2026-09-09 | Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study — Clin Cancer Res ([PMID 42714840](https://pubmed.ncbi.nlm.nih.gov/42714840/){target="_blank" rel="noopener"}) | early-stage-and-perioperative-therapy |
| 2026-09-08 | Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial — JAMA ([PMID 42574006](https://pubmed.ncbi.nlm.nih.gov/42574006/){target="_blank" rel="noopener"}) | egfr-disease, systemic-therapy |
| 2026-09-06 | Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial — Lancet ([PMID 42702214](https://pubmed.ncbi.nlm.nih.gov/42702214/){target="_blank" rel="noopener"}) | early-stage-and-perioperative-therapy |
| 2026-09-03 | Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer — N Engl J Med ([PMID 42685317](https://pubmed.ncbi.nlm.nih.gov/42685317/){target="_blank" rel="noopener"}) | kras-braf-met-her2 |
| 2026-09-02 | Long-term exposure to fine particulate matter constituents and lung cancer risk in Chinese never-smokers — J Hazard Mater ([PMID 42828982](https://pubmed.ncbi.nlm.nih.gov/42828982/){target="_blank" rel="noopener"}) | epidemiology-and-risk-factors |
| 2026-09-02 | Barriers and Facilitators to Shared Decision-Making in EGFRm Non-Small Cell Lung Cancer: Patient Perspectives — Patient Prefer Adherence ([PMID 42799215](https://pubmed.ncbi.nlm.nih.gov/42799215/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-09-02 | Long-term efficacy and adherence of a lung cancer screening strategy with extended LDCT intervals: Results from the BioMILD trial — Lung Cancer ([PMID 42777510](https://pubmed.ncbi.nlm.nih.gov/42777510/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2026-09-02 | Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy — J Thorac Oncol ([PMID 42767607](https://pubmed.ncbi.nlm.nih.gov/42767607/){target="_blank" rel="noopener"}) | egfr-disease |
| 2026-09-02 | Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation — Signal Transduct Target Ther ([PMID 42764281](https://pubmed.ncbi.nlm.nih.gov/42764281/){target="_blank" rel="noopener"}) | clinical-trials-landscape, early-stage-and-perioperative-therapy |
| 2026-09-01 | Genomic and transcriptomic landscape of spread through air spaces in stage 1 lung adenocarcinoma — Br J Cancer ([PMID 42760303](https://pubmed.ncbi.nlm.nih.gov/42760303/){target="_blank" rel="noopener"}) | histology-and-classification |
| 2026-09-01 | Germline EGFR T790M mutation and lung cancer risk — Science ([PMID 42752144](https://pubmed.ncbi.nlm.nih.gov/42752144/){target="_blank" rel="noopener"}) | epidemiology-and-risk-factors |
| 2026-09-01 | Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRAS(G12D) mutations: a phase 1 trial — Nat Med ([PMID 42745055](https://pubmed.ncbi.nlm.nih.gov/42745055/){target="_blank" rel="noopener"}) | kras-braf-met-her2 |
| 2026-09-01 | Long-term exposure to wildfire-related PM(2·5) and overall survival of older patients with lung cancer: a retrospective, registry-based cohort study — Lancet Oncol ([PMID 42743939](https://pubmed.ncbi.nlm.nih.gov/42743939/){target="_blank" rel="noopener"}) | epidemiology-and-risk-factors |
| 2026-09-01 | Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB-IIIA NSCLC: Exploratory 8-Year Overall Survival Landmark Update from the ADAURA Trial — J Thorac Oncol ([PMID 42732874](https://pubmed.ncbi.nlm.nih.gov/42732874/){target="_blank" rel="noopener"}) | early-stage-and-perioperative-therapy, egfr-disease |
| 2026-09-01 | Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2 — Lung Cancer ([PMID 42728193](https://pubmed.ncbi.nlm.nih.gov/42728193/){target="_blank" rel="noopener"}) | egfr-disease |
| 2026-09-01 | Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial — Lancet Oncol ([PMID 42727592](https://pubmed.ncbi.nlm.nih.gov/42727592/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-09-01 | Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial — Lancet Oncol ([PMID 42636834](https://pubmed.ncbi.nlm.nih.gov/42636834/){target="_blank" rel="noopener"}) | early-stage-and-perioperative-therapy |
| 2026-09-01 | Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial — Lancet Oncol ([PMID 42636833](https://pubmed.ncbi.nlm.nih.gov/42636833/){target="_blank" rel="noopener"}) | egfr-disease, immunotherapy |
| 2026-08-02 | Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial — J Clin Oncol ([PMID 42664473](https://pubmed.ncbi.nlm.nih.gov/42664473/){target="_blank" rel="noopener"}) | early-stage-and-perioperative-therapy |
| 2026-08-02 | Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial — Signal Transduct Target Ther ([PMID 42660909](https://pubmed.ncbi.nlm.nih.gov/42660909/){target="_blank" rel="noopener"}) | early-stage-and-perioperative-therapy, egfr-disease |
| 2026-08-01 | Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer — Nat Commun ([PMID 42706268](https://pubmed.ncbi.nlm.nih.gov/42706268/){target="_blank" rel="noopener"}) | early-stage-and-perioperative-therapy |
| 2026-08-01 | Financial toxicity among patients with lung cancer: a systematic review and meta-analysis — Front Public Health ([PMID 42661720](https://pubmed.ncbi.nlm.nih.gov/42661720/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-08-01 | Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3 — J Clin Oncol ([PMID 42607282](https://pubmed.ncbi.nlm.nih.gov/42607282/){target="_blank" rel="noopener"}) | guidelines |
| 2026-08-01 | Biomarkers of nivolumab benefit in resectable non-small cell lung cancer — Nature ([PMID 42587156](https://pubmed.ncbi.nlm.nih.gov/42587156/){target="_blank" rel="noopener"}) | early-stage-and-perioperative-therapy |
| 2026-07-28 | Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial — JAMA ([PMID 42307937](https://pubmed.ncbi.nlm.nih.gov/42307937/){target="_blank" rel="noopener"}) | clinical-trials-landscape, egfr-disease |
| 2026-07-09 | Ensartinib in Resected ALK-Positive Non-Small-Cell Lung Cancer — N Engl J Med ([PMID 42418775](https://pubmed.ncbi.nlm.nih.gov/42418775/){target="_blank" rel="noopener"}) | alk-ros1-and-fusion-drivers, clinical-trials-landscape, early-stage-and-perioperative-therapy |
| 2026-07-07 | Ifebemtinib plus garsorasib as first-line treatment for KRAS(G12C)-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial — Lancet Respir Med ([PMID 42413526](https://pubmed.ncbi.nlm.nih.gov/42413526/){target="_blank" rel="noopener"}) | kras-braf-met-her2 |
| 2026-07-02 | SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer — J Clin Oncol ([PMID 42507968](https://pubmed.ncbi.nlm.nih.gov/42507968/){target="_blank" rel="noopener"}) | immunotherapy |
| 2026-06-03 | Living With ALK Fusion-Positive NSCLC: A French Nationwide Survey of the Psychosocial Impact Among Patients, Caregivers, and Health Care Professionals — JTO Clin Res Rep ([PMID 42823962](https://pubmed.ncbi.nlm.nih.gov/42823962/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-06-02 | ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab — J Thorac Oncol ([PMID 42336205](https://pubmed.ncbi.nlm.nih.gov/42336205/){target="_blank" rel="noopener"}) | early-stage-and-perioperative-therapy |
| 2026-05-02 | Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study — Ann Oncol ([PMID 42217582](https://pubmed.ncbi.nlm.nih.gov/42217582/){target="_blank" rel="noopener"}) | alk-ros1-and-fusion-drivers |
| 2026-05-02 | Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1 — J Clin Oncol ([PMID 42190143](https://pubmed.ncbi.nlm.nih.gov/42190143/){target="_blank" rel="noopener"}) | guidelines |
| 2026-05-02 | Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1 — J Clin Oncol ([PMID 42190141](https://pubmed.ncbi.nlm.nih.gov/42190141/){target="_blank" rel="noopener"}) | guidelines |
| 2026-05-01 | Diagnosis of the Novel IASLC Grading System Using Intraoperative Frozen Section (ECTOP-1014): A Prospective, Multicenter Clinical Trial — Ann Thorac Surg ([PMID 42119754](https://pubmed.ncbi.nlm.nih.gov/42119754/){target="_blank" rel="noopener"}) | histology-and-classification |
| 2026-04-02 | Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief Report — J Thorac Oncol ([PMID 42061572](https://pubmed.ncbi.nlm.nih.gov/42061572/){target="_blank" rel="noopener"}) | egfr-disease |
| 2026-04-02 | Integrating Histologic Descriptors Into the Ninth Edition TNM Staging Improves Prognostic Stratification of Lung Adenocarcinoma — J Thorac Oncol ([PMID 42055159](https://pubmed.ncbi.nlm.nih.gov/42055159/){target="_blank" rel="noopener"}) | histology-and-classification |
| 2026-02-02 | ctDNA guided immunotherapy in patients with advanced non-small cell lung cancer: a nationwide Danish, randomised, intervention study (PRELUCA-PRediction in LUng CAncer Treatment) - study protocol — BMJ Open ([PMID 41628935](https://pubmed.ncbi.nlm.nih.gov/41628935/){target="_blank" rel="noopener"}) | biomarkers |
| 2026-01-01 | Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials — J Thorac Oncol ([PMID 41534788](https://pubmed.ncbi.nlm.nih.gov/41534788/){target="_blank" rel="noopener"}) | clinical-trials-landscape, egfr-disease |
| 2025-12-01 | Risk-Adapted Lung Cancer Screening Starting Ages for Former Smokers — JAMA Netw Open ([PMID 41632141](https://pubmed.ncbi.nlm.nih.gov/41632141/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2025-12-01 | Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma — Nature ([PMID 41372401](https://pubmed.ncbi.nlm.nih.gov/41372401/){target="_blank" rel="noopener"}) | molecular-landscape |
| 2025-12-01 | Common Determinants of Lung Cancer Screening Uptake in Three High-Risk and Underserved Communities — J Am Coll Radiol ([PMID 41338709](https://pubmed.ncbi.nlm.nih.gov/41338709/){target="_blank" rel="noopener"}) | screening-and-early-detection |
| 2025-11-01 | Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study — Lancet Oncol ([PMID 41232542](https://pubmed.ncbi.nlm.nih.gov/41232542/){target="_blank" rel="noopener"}) | screening-and-early-detection |
Trials — what has moved¶
59 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 2 |
| trial records updated in the last month | 7 |
| trial records updated in the last 2 months | 15 |
| trial records updated in the last 3 months | 18 |
| trial records updated in the last 6 months | 27 |
| trial records updated in the last year | 40 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-10-06 | Testing the Addition of the Drug Atezolizumab to the Usual Radiation T | PHASE3 | 417 | Overall Survival | 42 | 274 | 99 |
| 2026-04-16 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Soli | PHASE1, PHASE2 | 857 | Phase 1: Maximum Tolerated Dose (MTD) | 945 | 1714 | 350 |
| 2026-02-25 | Comparing Smoking Cessation Interventions Among Underserved Patients R | NA | 3228 | Biochemically Confirmed Smoking Abstinence Sustained for 6 Months | 0 | 0 | 8 |
| 2026-02-02 | A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intr | PHASE3 | 418 | For All Regions Other Than the European Union (EU) and Others Acceptin | 123 | 408 | 104 |
| 2025-05-11 | Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) Wit | PHASE3 | 448 | Event-free Survival (EFS) | 164 | 374 | 139 |
| 2024-12-04 | A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzu | PHASE2 | 72 | ICR-assessed ORR (Objective Response Rate) | 41 | 72 | 41 |
| 2024-05-29 | A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, | PHASE3 | 308 | Progression-Free Survival (PFS) According to Response Evaluation Crite | 104 | 300 | 70 |
| 2024-03-20 | Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (w | PHASE2 | 373 | Overall Response Rate (ORR) by Blinded Independent Review Committee (B | 487 | 874 | 707 |
49 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| alk-ros1-and-fusion-drivers | 2026-10-05 | 4 | 29 |
| clinical-trials-landscape | 2026-10-05 | 12 | 37 |
| egfr-disease | 2026-10-05 | 15 | 42 |
| screening-and-early-detection | 2026-10-05 | 6 | 32 |
| early-stage-and-perioperative-therapy | 2026-10-03 | 14 | 40 |
| guidelines | 2026-10-02 | 4 | 36 |
| immunotherapy | 2026-10-02 | 3 | 29 |
| kras-braf-met-her2 | 2026-10-02 | 5 | 31 |
| systemic-therapy | 2026-10-02 | 6 | 38 |
| epidemiology-and-risk-factors | 2026-09-02 | 3 | 28 |
| patient-experience-and-advocacy | 2026-09-02 | 4 | 33 |
| histology-and-classification | 2026-09-01 | 3 | 31 |
| biomarkers | 2026-02-02 | 1 | 28 |
| molecular-landscape | 2025-12-01 | 1 | 25 |
| overview | 2025-07-02 | 0 | 30 |
| staging | 2024-12-01 | 0 | 25 |
| red-flags-and-safety-concerns | 2024-06-02 | 0 | 25 |
| molecular-testing | 2024-05-01 | 0 | 25 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.